Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.08) by 2800 percent. This is a 89.59 percent increase over losses of $(22.28) per share from the same period last year. The company reported quarterly sales of $148.000 thousand which missed the analyst consensus estimate of $25.000 million by 99.41 percent.